Charles River Labs Announces First-Quarter 2025 Results and Raises Guidance

Details

(CRL) reported first-quarter 2025 financial results with a slight decrease in revenue of 2.7% to $984.2 million and a GAAP net income of $25.5 million, or $0.50 per share. Non-GAAP net income increased to $119.1 million, or $2.34 per share. The company repurchased $350 million of common stock and raised its 2025 financial guidance for revenue and earnings per share.

Items reported

Exhibits (1)

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.